Protective effect of the vasopressin agonist terlipressin in a rat model of contrast-induced nephropathy

Am J Nephrol. 2011;33(3):269-76. doi: 10.1159/000324764. Epub 2011 Mar 4.

Abstract

Background/aims: Contrast-induced nephropathy (CIN) remains a leading cause of iatrogenic acute renal failure. Terlipressin, a long-acting analog of vasopressin, may improve renal function. This study aimed to investigate the possible protective effect of terlipressin against the development of experimental CIN in rats.

Methods: Wistar albino rats (n = 32) were allocated randomly into four equal groups of 8 each, i.e. control, terlipressin, contrast media (CM), and terlipressin plus contrast media (TCM). CIN was induced by intravenous administration of indomethacin (10 mg/kg), N-nitro L-arginine methyl ester (L-NAME, 10 mg/kg, twice at 15 and 30 min), and high-osmolar contrast media meglumine amidotrizoate 60%. Renal function parameters, kidney histology, and tubular expression of vascular endothelial growth factor (VEGF) were determined.

Results: Mean serum creatinine levels were decreased (p < 0.05) and creatinine clearance (p < 0.05) increased in the TCM group compared with the CM group. Notably, rats in the TCM group displayed less tubular necrosis (p < 0.05), medullary congestion (p < 0.05), and a reduced tubular expression of VEGF (p < 0.05) compared with the CM group.

Conclusion: These results demonstrate that terlipressin can inhibit the development of CIN.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Kidney Injury / chemically induced*
  • Acute Kidney Injury / prevention & control
  • Animals
  • Contrast Media / adverse effects*
  • Disease Models, Animal
  • Kidney Function Tests
  • Lypressin / analogs & derivatives*
  • Lypressin / therapeutic use
  • Rats
  • Rats, Inbred BB
  • Terlipressin
  • Vasoconstrictor Agents / therapeutic use*
  • Vasopressins / agonists*

Substances

  • Contrast Media
  • Vasoconstrictor Agents
  • Vasopressins
  • Lypressin
  • Terlipressin